Enveric Biosciences (ENVB) Stock Price, News & Analysis

Company Overview

Enveric Biosciences is a clinical-stage biopharmaceutical company focused on the discovery and development of novel psychedelic-based therapeutics for the treatment of psychiatric and neurological disorders. The company’s research platform leverages proprietary medicinal chemistry to design, synthesize and optimize molecules derived from established psychoactive compounds, with a goal of improving safety, efficacy and tolerability compared with traditional formulations.

Enveric’s preclinical pipeline features synthetic analogs of ibogaine, psilocybin and MDMA, each engineered to enhance therapeutic outcomes in conditions such as post-traumatic stress disorder, major depressive disorder and anxiety. In parallel with pharmacology studies, the company is advancing formulation development, toxicology evaluations and analytical methods to support regulatory submissions and clinical trial readiness.

The company emphasizes a robust regulatory strategy and plans to file investigational new drug (IND) applications in the United States and Canada. Enveric collaborates with academic institutions, contract research organizations and clinical advisors to validate its drug candidates in emerging psychiatric therapy paradigms, including adjunctive use alongside psychotherapy.

Enveric Biosciences trades on the NASDAQ under the ticker ENVB, following a corporate rebranding from FSD Pharma in October 2021 to reflect its exclusive focus on psychedelic medicine. The company is pursuing strategic partnerships and geographic expansion across North America and Europe to accelerate clinical development and future commercialization of its pipeline assets.

Key Stats

• Today's Range: $1.30 to $1.43
• 50-Day Range: $1.28 to $5.32
• 52-Week Range: $1.26 to $17.64
• Volume: 98,663 shs
• Average Volume: 210,329 shs
• Market Capitalization: $4.97 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Enveric Biosciences Stock Analysis - MarketRank™

Enveric Biosciences scored higher than 14% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Enveric Biosciences has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Enveric Biosciences has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Enveric Biosciences is -0.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Enveric Biosciences is -0.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Enveric Biosciences has a P/B Ratio of 0.19. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.74% of the float of Enveric Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Enveric Biosciences has a short interest ratio ("days to cover") of 0.14, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Enveric Biosciences has recently decreased by 77.08%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Enveric Biosciences does not currently pay a dividend.

Dividend Growth

Enveric Biosciences does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Enveric Biosciences this week, compared to 2 articles on an average week.

MarketBeat Follows

9 people have added Enveric Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 350% compared to the previous 30 days.

Company Ownership

• Score: 0.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Enveric Biosciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

2.41% of the stock of Enveric Biosciences is held by insiders.

Percentage Held by Institutions

13.82% of the stock of Enveric Biosciences is held by institutions.

Company Calendar

• Last Earnings: 5/15/2026
• Today: 6/23/2026
• Next Earnings (Estimated): 8/17/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ENVB
• CIK: 890821
• Web: jaypharma.co
• Phone: (239) 302-1707
• Fax: 732-243-9254
• Employees: 20
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($23.54)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$8.77 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -220.97%
• Return on Assets: -177.47%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 11.66
• Quick Ratio: 11.66

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $7.00 per share
• Price / Book: 0.19

Miscellaneous

• Outstanding Shares: 3,682,000
• Free Float: 3,593,000
• Market Cap: $4.97 million
• Optionable: Not Optionable
• Beta: 1.12